Diversa Achieves Milestone Under XOMA Antibody Agreement

Diversa and XOMA announced the achievement of a milestone under their therapeutic antibody generation and optimization and license agreement for the successful generation of an antibody that binds with sub-picomolar affinity to an undisclosed XOMA target. The milestone achievement will result in an undisclosed payment to Diversa. "This milestone further demonstrates Diversa's ability to generate high-quality antibody product candidates through its technologies," said Jay M. Short, Ph.D., president and chief executive officer of Diversa Corporation.

()a href="http://biz.yahoo.com/prnews/050601/law040.html?.v=11" target="_blank">Yahoo News